Pre-clinical safety testing supporting clinical use of allogeneic multipotent adult progenitor cells

References

• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–7
   PubMed Web of Science ®Google Scholar
• Anjos-Afonso F, Bonnet D. Nonhematopoietic/endothelial SSEA-1+ cells define the most primitive progenitors in the adult murine bone marrow mesenchymal compartment. Blood 2007; 109: 1298–306
   PubMed Web of Science ®Google Scholar
• Owen M, Friedenstein AJ. Stromal stem cells: marrow-derived osteogenic precursors. Ciba Found Symp 1988; 136: 42–60
   PubMedGoogle Scholar
• Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–4
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143–7
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Campbell FR, et al. A population of very small embryonic-like (VSEL) CXCR4(+)SSEA-1(+)Oct-4+ stem cells identified in adult bone marrow. Leukemia 2006; 20: 857–69
   PubMed Web of Science ®Google Scholar
• Yoon YS, Wecker A, Heyd L, et al. Clonally expanded novel multipotent stem cells from human bone marrow regenerate myocardium after myocardial infarction. J Clin Invest 2005; 115: 326–38
   PubMed Web of Science ®Google Scholar
• Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41–9
   PubMed Web of Science ®Google Scholar
• Jiang Y, Vaessen B, Lenvik T, et al. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol 2002; 30: 896–904
   PubMed Web of Science ®Google Scholar
• D'Ippolito G, Diabira S, Howard GA, et al. Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117: 2971–81
   PubMed Web of Science ®Google Scholar
• Mays RW, van't Hof W, Ting AE, et al. Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin Biol Ther 2007; 7: 173–84
   PubMed Web of Science ®Google Scholar
• Pittenger MF, Martin BJ. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 2004; 95: 9–20
   PubMed Web of Science ®Google Scholar
• Ting AE, Mays RW, Frey MR, et al. Therapeutic pathways of adult stem cell repair. Crit Rev Oncol Hematol 2008; 65: 81–93
   PubMedGoogle Scholar
• Dai W, Hale SL, Martin BJ, et al. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation 2005; 112: 214–23
   PubMed Web of Science ®Google Scholar
• Van't Hof W, Mal N, Huang Y, et al. Direct delivery of syngeneic and allogeneic large-scale expanded multipotent adult progenitor cells improves cardiac function after myocardial infarct. Cytotherapy 2007; 9: 477–87
   PubMed Web of Science ®Google Scholar
• Le Blanc K. Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy 2006; 8: 559–61
   PubMed Web of Science ®Google Scholar
• Tyndall A, Walker UA, Cope A , et al. Immunomodulatory properties of mesenchymal stem cells: a review based on an interdisciplinary meeting held at the Kennedy Institute of Rheumatology Division, London, UK, 31 October 2005. Arthritis Res Ther 2007;9:301.
   Google Scholar
• Kebriaei P, Isola L, Bahceci E, et al. Phase II trial of Prochymal™ (ex-vivo cultured adult human mesenchymal stem cells) and corticosteroids as primary treatment for acute graft-vs-host disease (aGVHD). ASH Annu Meet Abstr 2006; 108: 3231
   Google Scholar
• Le Blanc K, Ringden O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 2006; 18: 586–91
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Immunomodulation by mesenchymal stem cells and clinical experience. J Intern Med 2007; 262: 509–25
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Koc ON, Devine SM, et al. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–98
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Rasmusson I, Sundberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–41
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Use of mesenchymal stem cells for the prevention of immune complications of hematopoietic stem cell transplantation. Haematologica 2005; 90: 438
   Google Scholar
• Ringden O, Uzunel M, Rasmusson I, et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006; 81: 1390–7
   PubMed Web of Science ®Google Scholar
• Perry R, Miller D, Deans R. Clinical scale expansion of human pluripotent stem cells. ASH Annu Meet Abstr 2005; 106: 1060
   Google Scholar
• Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I. The roles of minor H antigens and endotoxin. Blood 1996; 88: 3230–9
   PubMed Web of Science ®Google Scholar
• Overton WR. Modified histogram subtraction technique for analysis of flow cytometry data. Cytometry 1988; 9: 619–26
   PubMedGoogle Scholar
• Kohn DF, Clifford CB. Biology and disease of rats. Laboratory Animal Medicine2nd ed, JGAL Fox, FM Loew, FW Quimby. Elsevier Science, New York 2002; 121–65
   Google Scholar
• Barry FP, Murphy JM, English K, et al. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev 2005; 14: 252–65
   PubMed Web of Science ®Google Scholar
• Le Blanc K, Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 321–34
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499–506
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Westerhuis G, Kruisselbrink AB, et al. Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting. Blood 2006; 108: 2114–20
   PubMed Web of Science ®Google Scholar
• Sundin M, Ringden O, Sundberg B, et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 2007; 92: 1208–15
   PubMed Web of Science ®Google Scholar
• Cho PS, Messina DJ, Hirsh EL, et al. Immunogenicity of umbilical cord tissue derived cells. Blood 2007; 111: 430–438
   Google Scholar
• Halme DG, Kessler DA. FDA regulation of stem-cell-based therapies. N Engl J Med 2006; 355: 1730–5
   PubMed Web of Science ®Google Scholar
• Spees JL, Gregory CA, Singh H, et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004; 9: 747–56
   PubMed Web of Science ®Google Scholar
• Verfaillie C, Weisdorf D, Haake R, et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8: 177–84
   PubMed Web of Science ®Google Scholar
• Prockop DJ, Olson SD. Clinical trials with adult stem/progenitor cells for tissue repair: let's not overlook some essential precautions. Blood 2007; 109: 3147–51
   PubMed Web of Science ®Google Scholar
• Serafini M, Dylla SJ, Oki M, et al. Hematopoietic reconstitution by multipotent adult progenitor cells: precursors to long-term hematopoietic stem cells. J Exp Med 2007; 204: 129–39
   PubMed Web of Science ®Google Scholar
• Tolar J, O'Shaughnessy MJ, Panoskaltsis-Mortari A, et al. Host factors that impact the biodistribution and persistence of multipotent adult progenitor cells. Blood 2006; 107: 4182–8
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Haynesworth SE, Gerson SL, et al. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–64
   PubMed Web of Science ®Google Scholar